Skip to main content
. 2014 Jan 7;9(1):e85155. doi: 10.1371/journal.pone.0085155

Figure 3. Effects of chronic GRN163L on cellular lifespan.

Figure 3

A) Pancreatic cancer cell lines CAPAN1 and CD18 were selected for these studies. Every 2–3 days, each lines was given either no drug (vehicle), GRN163L (1 µM) or the Mismatched oligo (1 µM). Once a week, cells were counted and the results are plotted as the number of population doublings achieved as a function of time. Every other week, samples were put aside for TRF analysis (DNA) or frozen down as backup. B,C) Growth curves of the drug-treated CAPAN1 (B) and CD18 (C) cells are shown.